Lasers in surgery and medicine · 2025
Fractional CO2 Laser and Estrogen Ointment: A Novel Combined Approach for Treating Vulvar Lichen Sclerosus in Postmenopausal Women.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chen Yuanyuan, He Haizhen, Li Xiaodan, Chen Haitang, Huang Lingxiao, Pan Jiajia, Ni Feifei
Аннотация
BACKGROUND: Vulvar lichen sclerosus (VLS) is a chronic inflammatory condition predominantly affecting postmenopausal women, often leading to significant discomfort and impaired quality of life. Current treatments, such as topical corticosteroids, have limitations in efficacy and long-term safety. Fractional CO2 laser therapy has emerged as a promising modality for managing VLS, but its combination with topical estrogen remains underexplored.
OBJECTIVE: This study aimed to evaluate the efficacy and safety of combined fractional CO2 laser and topical estrogen therapy in managing VLS in postmenopausal women.
METHODS: A randomized controlled trial was conducted involving 60 postmenopausal women diagnosed with VLS. Participants were divided into two groups: the intervention group received fractional CO2 laser therapy combined with topical estrogen ointment, while the control group received topical estrogen alone. Efficacy was defined as a significant reduction in vulvar lichen sclerosus symptom score (VLSSS), assessed at baseline, 3 months, and 6 months. Secondary outcomes included histopathological changes and patient-reported quality of life measures.
RESULTS: At both 3 months and 1 year after treatment, the intervention group showed a significant reduction in VLSSS compared to the control group (p < 0.001). Histopathological analysis demonstrated reduced inflammation and fibrosis. Patient-reported outcomes revealed significant improvements in sexual function (FSFI) and quality of life (CECA10) in the combined therapy group. Additionally, the recurrence rate at 1 year was significantly lower in the intervention group (17.14%) than in the control group (31.43%, p < 0.001). No severe adverse events were reported.
LIMITATIONS: The study's sample size was relatively small, and the follow-up period was limited to 6 months, which may not capture long-term outcomes. Additionally, the single-center design may limit generalizability.
CONCLUSION: Combined fractional CO2 laser and topical estrogen therapy is a safe and effective approach for managing VLS in postmenopausal women, offering significant symptom relief and improved quality of life. Further studies with larger cohorts and longer follow-up are warranted to confirm these findings.
OBJECTIVE: This study aimed to evaluate the efficacy and safety of combined fractional CO2 laser and topical estrogen therapy in managing VLS in postmenopausal women.
METHODS: A randomized controlled trial was conducted involving 60 postmenopausal women diagnosed with VLS. Participants were divided into two groups: the intervention group received fractional CO2 laser therapy combined with topical estrogen ointment, while the control group received topical estrogen alone. Efficacy was defined as a significant reduction in vulvar lichen sclerosus symptom score (VLSSS), assessed at baseline, 3 months, and 6 months. Secondary outcomes included histopathological changes and patient-reported quality of life measures.
RESULTS: At both 3 months and 1 year after treatment, the intervention group showed a significant reduction in VLSSS compared to the control group (p < 0.001). Histopathological analysis demonstrated reduced inflammation and fibrosis. Patient-reported outcomes revealed significant improvements in sexual function (FSFI) and quality of life (CECA10) in the combined therapy group. Additionally, the recurrence rate at 1 year was significantly lower in the intervention group (17.14%) than in the control group (31.43%, p < 0.001). No severe adverse events were reported.
LIMITATIONS: The study's sample size was relatively small, and the follow-up period was limited to 6 months, which may not capture long-term outcomes. Additionally, the single-center design may limit generalizability.
CONCLUSION: Combined fractional CO2 laser and topical estrogen therapy is a safe and effective approach for managing VLS in postmenopausal women, offering significant symptom relief and improved quality of life. Further studies with larger cohorts and longer follow-up are warranted to confirm these findings.